Eurobio Scientific (ALERS) | Financial Analysis & Statements
Eurobio Scientific S.A. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2018Income Metrics
EPS (Diluted)
€0.00
Balance Sheet Metrics
Total Assets
257.2M
Total Liabilities
78.3M
Shareholders Equity
178.9M
Debt to Equity
0.44
Cash Flow Metrics
Revenue & Profitability Trend
Annual Income Flow
2024
Eurobio Scientific Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 154.6M | 130.0M | 152.6M | 184.7M | 189.2M |
| Cost of Goods Sold | 83.0M | 73.2M | 81.7M | 82.5M | 78.5M |
| Gross Profit | 71.6M | 56.8M | 70.9M | 102.2M | 110.7M |
| Gross Margin % | 46.3% | 43.7% | 46.5% | 55.3% | 58.5% |
| Operating Expenses | |||||
| Research & Development | 4.6M | 5.9M | 3.5M | 3.4M | 2.2M |
| Selling, General & Administrative | 45.5M | 33.5M | 31.0M | 24.5M | 22.5M |
| Other Operating Expenses | 3.5M | - | - | - | - |
| Total Operating Expenses | 53.6M | 39.4M | 34.5M | 27.9M | 24.7M |
| Operating Income | 9.8M | 10.1M | 30.9M | 70.1M | 81.2M |
| Operating Margin % | 6.3% | 7.8% | 20.2% | 38.0% | 42.9% |
| Non-Operating Items | |||||
| Interest Income | 1.5M | 1.1M | 43.0K | 0 | 1.0K |
| Interest Expense | 4.1M | 4.4M | 1.3M | 412.0K | 603.0K |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 6.3M | 7.0M | 29.7M | 71.3M | 80.9M |
| Income Tax | 2.3M | 2.1M | 4.7M | 10.8M | 7.4M |
| Effective Tax Rate % | 36.4% | 30.7% | 16.0% | 15.1% | 9.2% |
| Net Income | 4.0M | 4.8M | 24.9M | 60.5M | 73.5M |
| Net Margin % | 2.6% | 3.7% | 16.3% | 32.8% | 38.8% |
| Key Metrics | |||||
| EBITDA | 28.8M | 27.0M | 40.8M | 77.6M | 88.7M |
| EPS (Basic) | €0.39 | €0.43 | €2.20 | €5.58 | €6.56 |
| EPS (Diluted) | €0.39 | €0.43 | €2.20 | €5.57 | €6.53 |
| Basic Shares Outstanding | 10264089 | 11153061 | 11343171 | 10847723 | 11207149 |
| Diluted Shares Outstanding | 10264089 | 11153061 | 11343171 | 10847723 | 11207149 |
Income Statement Trend
Eurobio Scientific Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 21.8M | 49.3M | 47.5M | 92.9M | 65.1M |
| Short-term Investments | 1.3M | 39.7M | 38.4M | 9.5M | 456.0K |
| Accounts Receivable | 32.1M | 26.9M | 32.8M | 43.9M | 51.2M |
| Inventory | 26.9M | 21.4M | 21.7M | 16.3M | 12.9M |
| Other Current Assets | -1.0K | 2.0K | 1.0K | 1.0K | - |
| Total Current Assets | 89.6M | 143.9M | 148.7M | 173.6M | 135.2M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 11.6M | 11.3M | 3.2M | 3.0M | 16.3M |
| Goodwill | 272.4M | 270.8M | 270.8M | 40.0M | 47.4M |
| Intangible Assets | 34.6M | 35.4M | 39.2M | 3.6M | 5.5M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | -2.0K | 1.0K | -1.0K | -1.0K | - |
| Total Non-Current Assets | 167.6M | 172.4M | 182.0M | 36.3M | 37.1M |
| Total Assets | 257.2M | 316.3M | 330.7M | 209.9M | 172.3M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 15.3M | 13.0M | 13.0M | 7.0M | 7.5M |
| Short-term Debt | 2.8M | 15.1M | 15.3M | 5.2M | 15.4M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 1.8M | 1.6M | 803.0K | 588.0K | 1.4M |
| Total Current Liabilities | 44.1M | 52.9M | 57.3M | 36.1M | 48.0M |
| Non-Current Liabilities | |||||
| Long-term Debt | 31.3M | 86.2M | 99.0M | 11.1M | 14.9M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | -1.0K | -1.0K |
| Total Non-Current Liabilities | 34.2M | 88.3M | 100.4M | 12.9M | 16.5M |
| Total Liabilities | 78.3M | 141.2M | 157.7M | 49.0M | 64.5M |
| Equity | |||||
| Common Stock | 3.3M | 3.5M | 3.6M | 3.6M | 3.6M |
| Retained Earnings | - | - | - | - | - |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 178.9M | 175.2M | 173.0M | 160.9M | 107.8M |
| Key Metrics | |||||
| Total Debt | 34.1M | 101.3M | 114.3M | 16.4M | 30.4M |
| Working Capital | 45.4M | 91.0M | 91.4M | 137.5M | 87.2M |
Balance Sheet Composition
Eurobio Scientific Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 4.0M | 4.8M | 24.9M | 60.5M | 73.5M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | -4.3M | 8.3M | 8.8M | -3.7M | -28.3M |
| Operating Cash Flow | 1.9M | 15.0M | 35.0M | 57.3M | 45.8M |
| Investing Activities | |||||
| Capital Expenditures | -3.1M | -2.2M | -315.0K | -1.7M | -2.3M |
| Acquisitions | -10.1M | -4.5M | -132.2M | 0 | -2.2M |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -13.2M | -6.7M | -132.5M | -1.7M | -4.5M |
| Financing Activities | |||||
| Share Repurchases | -149.0K | -2.8M | -12.2M | -6.9M | -247.0K |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | 0 | 105.0M | 0 | 20.7M |
| Debt Repayment | -90.9M | -16.4M | -7.6M | -14.2M | -9.6M |
| Financing Cash Flow | -67.6M | -19.3M | 85.1M | -21.6M | 9.0M |
| Free Cash Flow | 13.4M | 22.7M | 40.2M | 64.1M | 52.6M |
| Net Change in Cash | -78.9M | -10.9M | -12.4M | 34.0M | 50.3M |
Cash Flow Trend
Eurobio Scientific Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
108.64
Forward P/E
21.15
Price to Book
1.33
Price to Sales
1.42
Profitability Ratios
Profit Margin
2.90%
Operating Margin
5.61%
Return on Equity
2.24%
Return on Assets
1.55%
Financial Health
Current Ratio
2.03
Debt to Equity
0.19
Beta
0.68
Per Share Data
EPS (TTM)
€0.22
Book Value per Share
€18.03
Revenue per Share
€15.06
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ALERS | 229.6M | 108.64 | 1.33 | 2.24% | 2.90% | 0.19 |
| Median Technologies | 188.6M | -3.61 | - | 74.31% | -94.04% | -1.15 |
| Guerbet S.A | 127.3M | 13.77 | 0.47 | -34.58% | -13.56% | 169.65 |
| Affluent Medical | 122.2M | -8.37 | 5.24 | -62.51% | -279.97% | 110.96 |
| Mauna Kea | 37.4M | -1.17 | -1.37 | 42.66% | -127.03% | -1.35 |
| Diagnostic Medical | 34.5M | -133.50 | 2.16 | -11.62% | -3.37% | 138.72 |
Financial data is updated regularly. All figures are in the company's reporting currency.